140 - CCS/CHFS 2025 GUIDELINE UPDATE FOR PHARMACOLOGIC MANAGEMENT OF HEART FAILURE WITH NON-REDUCED EJECTION FRACTION (LV EJECTION FRACTION > 40%)

Co-Chair(s)

• 

  Sean Virani, MD MSc MPH (he/him/his)

  President
  Canadian Cardiovascular Society
  St. Paul's Hospital | Providence Health Care
• 

  Shelley Zieroth, MD

  Cardiologist
  CHFS
  University of Manitoba

Presenter(s)

• 

  Natasha Aleksova, MD, MSc

  Cardiologist
  Toronto General Hospital
• 

  Eileen O'Meara, MD, FRCPC

  Associate professor
  Montreal Heart Institute
  Université de Montréal
• KA

  Kim Anderson, MD (she/her/hers)

  Cardiologist
  Dalhousie University
  Dalhousie University
• 

  Michael McDonald, MD FRCPC

  Associate Professor
  University of Toronto
  Toronto General Hospital
• 

  Stephanie Poon, MD, MSc, FRCPC

  Staff Cardiologist
  Sunnybrook Health Sciences Centre
  University of Toronto
• 

  Sean Virani, MD MSc MPH (he/him/his)

  President
  Canadian Cardiovascular Society
  St. Paul's Hospital | Providence Health Care
• 

  Shelley Zieroth, MD

  Cardiologist
  CHFS
  University of Manitoba

Moderator(s)

• CG

  Carolyn Gall Casey, BASc

  Director Guidelines and Knowledge Translation
  Canadian Cardiovascular Society

Planning Committee Member(s)

• 

  Sean Virani, MD MSc MPH (he/him/his)

  President
  Canadian Cardiovascular Society
  St. Paul's Hospital | Providence Health Care
• 

  Shelley Zieroth, MD

  Cardiologist
  CHFS
  University of Manitoba

Workshop Description: This workshop will present the latest Canadian Cardiovascular Society (CCS)/Canadian Heart Failure Society (CHFS) guideline updates on the pharmacologic management of heart failure with non-reduced ejection fraction (LVEF > 40%), encompassing both heart failure with mildly reduced and preserved ejection fraction. The session will highlight evidence-based therapies, and emerging treatments that improve morbidity and quality of life. Clinical cases and interactive discussion will guide participants to implement treatment plans that reflect the evolving understanding for this group of patients.

Presentations:

• Methodology - Natasha Aleksova
  
• SGLT2i - Eileen O'Meara
  
• MRA - Kim Anderson
  
• ARNI - Stephanie Poon
  
• GLP-ra - Michael McDonald

  Learning Objectives:

  At the end of this session participants will be able to:

  • integrate updated CCS/CHFS guideline recommendations for managing heart failure with mildly reduced and preserved ejection fraction using pharmacologic therapies;
  • identify patient subgroups likely to benefit from specific drug classes; and
  • tailor treatment strategies based on comorbidities and patient-specific factors to optimize heart failure outcomes.